Nontuberculous mycobacterial infections

Area of Science:

• Infectious Diseases
• Microbiology
• Immunology

Background:

• The acquired immunodeficiency syndrome (AIDS) pandemic has increased awareness of non-tuberculous mycobacteria (NTM) pathogenicity.
• Mycobacterium avium complex (MAC) is the most frequent systemic bacterial infection in AIDS patients, leading to disseminated disease in advanced HIV.
• Understanding NTM infections is crucial for managing opportunistic infections in immunocompromised individuals.

Purpose of the Study:

• To review the clinical syndromes caused by NTM in AIDS patients.
• To outline current and emerging therapeutic options for NTM infections in the context of HIV/AIDS.
• To highlight the impact of new antibiotics on managing MAC and other NTM.

Main Methods:

• Literature review of clinical syndromes and treatment strategies for NTM in AIDS.
• Analysis of the efficacy of macrolide antibiotics (clarithromycin, azithromycin) and rifabutin for MAC treatment and prophylaxis.
• Review of treatment regimens for Mycobacterium kansasii, including isoniazid, rifampin, and ethambutol.

Main Results:

• Macrolide antibiotics and rifabutin offer effective and well-tolerated treatment for MAC, prolonging survival and improving quality of life in AIDS patients.
• Preventive therapy with macrolides and rifabutin is beneficial for MAC in AIDS.
• Mycobacterium kansasii infections, presenting as pulmonary or disseminated disease in AIDS, are treatable with standard anti-tuberculosis drugs.

Conclusions:

• Effective therapeutic and preventive strategies exist for MAC and Mycobacterium kansasii in AIDS patients.
• Advances in antibiotic therapy, particularly macrolides, have significantly improved outcomes for MAC infections.
• Continued research and clinical vigilance are necessary to manage the spectrum of NTM infections in the evolving landscape of HIV/AIDS treatment.